静脈血栓塞栓症予防薬市場- 世界の産業規模、動向、機会、予測、タイプ別、最終用途別、地域別、競合別セグメント、2020～2030年

静脈血栓塞栓症予防薬の世界市場規模は、2024年に68億2,000万米ドルとなり、2030年のCAGRは5.58%で、予測期間には94億6,000万米ドルに達する見込みです。

静脈血栓塞栓症（VTE）予防薬の世界市場は、深部静脈血栓症（DVT）と肺塞栓症（PE）の発生率が上昇しており、特に入院患者や手術後の患者において重大な健康リスクをもたらしているため、着実な成長を遂げています。未治療のVTEに伴う合併症に対する意識の高まりにより、抗凝固薬などの薬理学的介入や圧迫装置などの機械的方法を含む予防的手段が広く採用されるようになりました。医療インフラの拡大と診断技術の進歩により、リスクのある患者の早期発見と治療が可能になっています。病院や外来医療環境における患者安全プロトコルの重視の高まりが、VTE予防策の採用をさらに後押ししています。高リスク患者の特定における人工知能（AI）と予測分析の統合は、治療成績の向上と資源配分の最適化をもたらしています。

がん、心血管疾患、肥満などの慢性疾患の有病率の増加が、効果的なVTE予防に対する需要の高まりに寄与しています。従来の抗凝固薬に代わる、より安全で利便性の高い選択肢として、直接経口抗凝固薬（DOAC）の採用が進んでいます。外来治療や低侵襲手術へのシフトは、病院環境以外の予防対策の必要性を加速させています。間欠的空気圧迫（IPC）システムや段階的圧迫ストッキングなどの機械的予防装置の技術的進歩により、患者のコンプライアンスと転帰が改善されています。血栓予防を促進する医療施策と償還プログラムが市場の成長を強化しています。生物製剤や次世代抗凝固薬の研究が進むことで、革新的な治療オプションが導入され、効果的な血栓予防を確保しながら出血リスクを低減できると期待されています。VTEに罹患しやすい高齢者が増加しているため、予防療法に大きな成長の可能性があります。

新興国市場では、VTE予防の認知度や利用しやすさに限界があり、市場拡大の大きな障壁となっています。新規の抗凝固療法や機械的デバイスに関連する高額なコストは、特に低所得層では購入可能な価格を制限しています。出血リスクや抗凝固薬の潜在的な副作用に対する懸念による患者のためらいが、採用率に影響しています。新薬や医療機器の厳しい承認プロセスが市場参入の遅れにつながり、先進的な予防法の選択肢が制限されます。特定の医療施設ではVTE予防ガイドラインが遵守されていないため、予防戦略の実施に一貫性がないです。複数の合併症を持つ患者におけるVTEリスク管理の複雑さは、医療提供者にさらなる課題を突きつけています。対象を絞った啓発プログラム、費用対効果の高い治療ソリューション、合理化された規制経路を通じてこれらの障壁に対処することが、世界静脈血栓塞栓症予防薬市場の持続的成長にとって極めて重要です。

主要市場促進要因

人口の高齢化

主要市場課題

予防薬のコスト

主要市場動向

デジタルヘルス統合

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の静脈血栓塞栓症予防薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（下肢、上肢）
  • 用途別（病院クリニック、外来医療センター、その他）
  • 企業別（2024年）
• 市場マップ
  • タイプ別
  • 最終用途別
  • 地域別

第5章 アジア太平洋の静脈血栓塞栓症予防薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の静脈血栓塞栓症予防薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の静脈血栓塞栓症予防薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の静脈血栓塞栓症予防薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの静脈血栓塞栓症予防薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 製品上市
• 合併と買収

第12章 世界の静脈血栓塞栓症予防薬市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 産業内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Arjo
• Encompass Group
• Argon Medical Devices
• MEGO AFEK
• Zenith Technical Innovations
• Cook Medical
• Bio Compression Systems
• ThermoTek USA
• Boston Scientific Corporation
• Cardinal Health（Medtronic）

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Venous Thromboembolism Prophylaxis Market was valued at USD 6.82 Billion in 2024 and is expected to reach USD 9.46 Billion in the forecast period with a CAGR of 5.58% through 2030. The Global Venous Thromboembolism (VTE) Prophylaxis Market is witnessing steady growth due to the rising incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE), which pose significant health risks, particularly among hospitalized and post-surgical patients. Increased awareness of the complications associated with untreated VTE has led to the widespread adoption of prophylactic measures, including pharmacological interventions such as anticoagulants and mechanical methods like compression devices. The expansion of healthcare infrastructure and advancements in diagnostic technologies are enabling early detection and treatment of at-risk patients. Growing emphasis on patient safety protocols in hospitals and ambulatory care settings is further driving the adoption of VTE prophylaxis. The integration of artificial intelligence (AI) and predictive analytics in identifying high-risk individuals is improving treatment outcomes and optimizing resource allocation.

Increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, and obesity is contributing to the rising demand for effective VTE prophylaxis. The adoption of direct oral anticoagulants (DOACs) as a safer and more convenient alternative to traditional anticoagulants is gaining traction. The shift towards outpatient care and minimally invasive surgeries is accelerating the need for preventive measures beyond hospital settings. Technological advancements in mechanical prophylaxis devices, such as intermittent pneumatic compression (IPC) systems and graduated compression stockings, are improving patient compliance and outcomes. Healthcare policies and reimbursement programs promoting thromboprophylaxis are strengthening market growth. Increasing research in biologics and next-generation anticoagulants is expected to introduce innovative treatment options, reducing bleeding risks while ensuring effective clot prevention. The rising geriatric population, which is more susceptible to VTE, presents significant growth potential for prophylactic therapies.

Limited awareness and accessibility of VTE prophylaxis in developing regions remain significant barriers to market expansion. High costs associated with novel anticoagulant therapies and mechanical devices restrict affordability, particularly in low-income populations. Patient hesitation due to concerns about bleeding risks and potential side effects of anticoagulants affects adoption rates. Stringent regulatory approval processes for new drugs and devices lead to delays in market entry, limiting the availability of advanced prophylactic options. The lack of adherence to VTE prevention guidelines in certain healthcare facilities results in inconsistent implementation of prophylaxis strategies. The complexity of managing VTE risks in patients with multiple comorbidities poses additional challenges for healthcare providers. Addressing these barriers through targeted awareness programs, cost-effective treatment solutions, and streamlined regulatory pathways will be crucial for the sustained growth of the Global Venous Thromboembolism Prophylaxis Market.

Key Market Drivers

Aging Population

The aging population is a significant driving force behind the growth of the Global Venous Thromboembolism (VTE) Prophylaxis Market. As the global population continues to age, there is a marked increase in the incidence of VTE-related health issues, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Elderly individuals are particularly vulnerable to VTE due to factors like reduced mobility, comorbidities, and alterations in blood composition. This demographic shift has led to a heightened demand for effective VTE prophylactic measures.

One primary reason for this increased demand is the higher prevalence of surgical procedures among older individuals. Surgical interventions, especially orthopedic and major surgeries, are known risk factors for VTE. The elderly population frequently undergoes joint replacements, cardiac surgeries, and other medical interventions, increasing their risk. Healthcare providers are acutely aware of this risk and are increasingly implementing prophylactic strategies, such as anticoagulant medications and mechanical devices, to minimize the likelihood of VTE in their elderly patients.

Furthermore, the elderly population's vulnerability to VTE is exacerbated by decreased mobility and lifestyle changes. Reduced physical activity and prolonged periods of immobility, such as extended bed rest or long flights, can significantly elevate the risk of blood clots. As the aging population seeks to maintain their mobility and quality of life, the demand for VTE prophylaxis becomes even more critical.

Pharmaceutical companies have responded to this growing need by developing anticoagulant medications with improved safety profiles and dosing regimens suitable for older patients. Additionally, medical device manufacturers have introduced more comfortable and efficient mechanical prophylaxis devices, ensuring that VTE prevention options are well-suited for elderly individuals.

Key Market Challenges

Cost of Prophylaxis

The price tag associated with VTE prevention, especially in the case of anticoagulant medications and mechanical devices, can be overwhelming for both healthcare systems and patients. This becomes particularly evident in regions with limited healthcare budgets or in countries where out-of-pocket expenses for medical treatments are high. Such expenses can deter individuals from seeking prophylactic measures, even when they are at risk of developing VTE.

Anticoagulant medications, while effective, often come with a high cost, especially the newer, more advanced drugs with better safety profiles and fewer side effects. For many patients, these medications need to be taken long-term, leading to escalating costs over time. Additionally, mechanical prophylaxis devices, such as intermittent pneumatic compression (IPC) pumps or advanced compression stockings, can also be pricey. While these devices are vital for patients who cannot take anticoagulants due to contraindications, their costs can be a significant barrier to widespread adoption.

Furthermore, the financial implications of VTE prophylaxis are not limited to the direct cost of medications and devices. Monitoring patients, especially those on anticoagulant medications, requires regular blood tests and follow-ups, incurring additional expenses. For many patients, especially those without comprehensive insurance coverage, these cumulative costs can be daunting.

Key Market Trends

Digital Health Integration

Digital health integration is emerging as a pivotal driver behind the growth of the Global Venous Thromboembolism (VTE) Prophylaxis Market. VTE, encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), affects up to 900,000 Americans annually, with an estimated 60,000 to 100,000 deaths each year. The integration of digital health technologies is revolutionizing VTE prophylaxis management, leading to more effective prevention and improved patient outcomes.

Electronic health records (EHRs) serve as a cornerstone in this integration, enabling healthcare providers to swiftly access patient histories, risk factors, and medication profiles. This real-time data access facilitates timely risk assessments, ensuring high-risk patients receive appropriate prophylactic measures. Studies have shown that implementing EHRs can reduce medication errors by 54% and adverse drug reactions by 36%, thereby enhancing patient safety.

Remote patient monitoring systems also play a vital role in enhancing VTE prevention. These systems allow continuous monitoring of patients post-discharge, tracking activity levels, vital signs, and medication adherence. Such surveillance is crucial, as more than one-third of VTE cases are associated with recent hospitalizations, with many events occurring after discharge. By detecting early warning signs of VTE development, healthcare teams can intervene promptly, significantly reducing incidence rates and improving patient safety.

Telemedicine platforms further contribute to VTE prophylaxis by facilitating virtual consultations, enabling healthcare providers to assess risk factors and guide prophylactic measures remotely. This approach is particularly beneficial given that as many as 70% of healthcare-associated VTE cases are preventable through measures such as anticoagulant medications or compression stockings. Remote consultations enhance patient education and engagement, promoting adherence to preventive strategies.

Key Market Players

• Arjo
• Encompass Group
• Argon Medical Devices
• MEGO AFEK
• Zenith Technical Innovations
• Cook Medical
• Bio Compression Systems
• ThermoTek USA
• Boston Scientific Corporation
• Cardinal Health (Medtronic)

Report Scope:

In this report, the Global Venous Thromboembolism Prophylaxis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Venous Thromboembolism Prophylaxis Market, By Type:

• Lower Extremity
• Upper Extremity

Venous Thromboembolism Prophylaxis Market, By End Use:

• Hospitals & Clinics
• Ambulatory care Centers
• Others

Venous Thromboembolism Prophylaxis Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Venous Thromboembolism Prophylaxis Market.

Available Customizations:

Global Venous Thromboembolism Prophylaxis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Venous Thromboembolism Prophylaxis Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Lower Extremity, Upper Extremity)
  • 4.2.2. By End Use (Hospitals & Clinics, Ambulatory care Centers, Others)
  • 4.2.3. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By End Use
  • 4.3.3. By Region

5. Asia Pacific Venous Thromboembolism Prophylaxis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By End Use
  • 5.2.3. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Venous Thromboembolism Prophylaxis Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By End Use
  • 5.3.2. India Venous Thromboembolism Prophylaxis Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By End Use
  • 5.3.3. Australia Venous Thromboembolism Prophylaxis Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By End Use
  • 5.3.4. Japan Venous Thromboembolism Prophylaxis Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By End Use
  • 5.3.5. South Korea Venous Thromboembolism Prophylaxis Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By End Use

6. Europe Venous Thromboembolism Prophylaxis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Venous Thromboembolism Prophylaxis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By End Use
  • 6.3.2. Germany Venous Thromboembolism Prophylaxis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By End Use
  • 6.3.3. Spain Venous Thromboembolism Prophylaxis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By End Use
  • 6.3.4. Italy Venous Thromboembolism Prophylaxis Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By End Use
  • 6.3.5. United Kingdom Venous Thromboembolism Prophylaxis Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By End Use

7. North America Venous Thromboembolism Prophylaxis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Venous Thromboembolism Prophylaxis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By End Use
  • 7.3.2. Mexico Venous Thromboembolism Prophylaxis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By End Use
  • 7.3.3. Canada Venous Thromboembolism Prophylaxis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By End Use

8. South America Venous Thromboembolism Prophylaxis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Venous Thromboembolism Prophylaxis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By End Use
  • 8.3.2. Argentina Venous Thromboembolism Prophylaxis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By End Use
  • 8.3.3. Colombia Venous Thromboembolism Prophylaxis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By End Use

9. Middle East and Africa Venous Thromboembolism Prophylaxis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Venous Thromboembolism Prophylaxis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By End Use
  • 9.3.2. Saudi Arabia Venous Thromboembolism Prophylaxis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By End Use
  • 9.3.3. UAE Venous Thromboembolism Prophylaxis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By End Use

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Venous Thromboembolism Prophylaxis Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Arjo
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Encompass Group
• 14.3. Argon Medical Devices
• 14.4. MEGO AFEK
• 14.5. Zenith Technical Innovations
• 14.6. Cook Medical
• 14.7. Bio Compression Systems
• 14.8. ThermoTek USA
• 14.9. Boston Scientific Corporation
• 14.10.Cardinal Health (Medtronic)

15. Strategic Recommendations

16. About Us & Disclaimer